Skip to main content
Top
Published in: Seminars in Immunopathology 2/2008

01-04-2008 | Review

Autoimmune retinopathy: A review and summary

Authors: John R. Heckenlively, Henry A. Ferreyra

Published in: Seminars in Immunopathology | Issue 2/2008

Login to get access

Abstract

Three main forms of autoimmune retinopathy (AIR) have been identified over the last 15 years: cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and nonneoplastic autoimmune retinopathy (npAIR). In this chapter, the term AIR will be used to encompass all three disorders where there is commonality to their features. Complicating the issue is that AIR can be a secondary complication of other conditions such as retinitis pigmentosa, ocular trauma, birdshot retinopathy, acute zonal occult outer retinopathy (AZOOR), or multiple evanescent white dot syndrome (MEWDS). The many forms of AIR tend to have common clinical features despite the fact that there has been no uniform set of anti-retinal antibodies circulating in these patients. Patients tend to have a wide variance of anti-retinal antibody activity often with three to six different antibodies found on immunoblots. Patients typically present with a sudden onset of photopsia, rapid visual loss, and abnormal electroretinograms (ERGs). Most patients have a panretinal degeneration without pigment deposits.
Literature
1.
2.
go back to reference Hooks JJ, Tso MOM, Detrick B (2001) Retinopathies associated with antiretinal antibodies. Clin Diagn Lab Immunol 8:853–858PubMedCrossRef Hooks JJ, Tso MOM, Detrick B (2001) Retinopathies associated with antiretinal antibodies. Clin Diagn Lab Immunol 8:853–858PubMedCrossRef
3.
go back to reference Koh AH, Hogg CR, Holder GE (2001) The incidence of negative ERG in clinical practice. Doc Ophthalmol 102(1):19–30PubMedCrossRef Koh AH, Hogg CR, Holder GE (2001) The incidence of negative ERG in clinical practice. Doc Ophthalmol 102(1):19–30PubMedCrossRef
4.
go back to reference Heckenlively J, Fawzi AA, Oversier J, Jordan BL, Aptsiauri N (2000) Autoimmune retinopathy; patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthal 118:1525–1533PubMed Heckenlively J, Fawzi AA, Oversier J, Jordan BL, Aptsiauri N (2000) Autoimmune retinopathy; patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthal 118:1525–1533PubMed
5.
go back to reference Cross S, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA (2003) Paraneo-plastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54:38–50 Cross S, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA (2003) Paraneo-plastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54:38–50
6.
go back to reference Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF (1976) Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 81:606–613PubMed Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF (1976) Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 81:606–613PubMed
7.
go back to reference Adamus G, Ren G, Weleber RG (2004) Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 4:5 Jun 4PubMedCrossRef Adamus G, Ren G, Weleber RG (2004) Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 4:5 Jun 4PubMedCrossRef
8.
go back to reference Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR (1993) Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 34(1):91–100PubMed Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR (1993) Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 34(1):91–100PubMed
9.
go back to reference Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL (1989) Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic nerve, and cancer cells. N Engl J Med 321:1589–1594PubMed Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL (1989) Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic nerve, and cancer cells. N Engl J Med 321:1589–1594PubMed
10.
go back to reference Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL (1992) The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 33:2768–2772PubMed Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL (1992) The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 33:2768–2772PubMed
11.
go back to reference Polans AS, Burton MD, Haley TL, Crabb JW, Palczewski K (1993) Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34:81–90PubMed Polans AS, Burton MD, Haley TL, Crabb JW, Palczewski K (1993) Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34:81–90PubMed
12.
go back to reference Jankowska R, Witkowska D, Porębska I, Kuropatwa M, Kurowska E, Gorczyca WA (2004) Serum antibodies to retinal antigens in lung cancer and sarcoidosis. Pathobiology 71:323–328PubMedCrossRef Jankowska R, Witkowska D, Porębska I, Kuropatwa M, Kurowska E, Gorczyca WA (2004) Serum antibodies to retinal antigens in lung cancer and sarcoidosis. Pathobiology 71:323–328PubMedCrossRef
13.
go back to reference Shiraga S, Adamus G (2002) Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 132:72–82PubMedCrossRef Shiraga S, Adamus G (2002) Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 132:72–82PubMedCrossRef
14.
go back to reference Adamus G, Amundson D, Seigel GM, Machnicki M (1998) Anti-enolase-a autoantibodies in cancer-associated retinopathhy: epitope mapping and cytotosicity on retinal cells. J Autoimmun 11:671–677PubMedCrossRef Adamus G, Amundson D, Seigel GM, Machnicki M (1998) Anti-enolase-a autoantibodies in cancer-associated retinopathhy: epitope mapping and cytotosicity on retinal cells. J Autoimmun 11:671–677PubMedCrossRef
15.
go back to reference Heckenlively JR, Aptsiauri N, Nusinowitz S, Peng C, Hargrave P (1996) Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations. Trans Am Ophthalmol Soc XCIV:179–206 Heckenlively JR, Aptsiauri N, Nusinowitz S, Peng C, Hargrave P (1996) Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations. Trans Am Ophthalmol Soc XCIV:179–206
16.
go back to reference Heckenlively J, Jordan B, Aptsiauri N (1999) An association of antiretinal antibodies and cystoid macular edema in retinitis pigmentosa patients. Am J Ophthalmol 127:565–578PubMedCrossRef Heckenlively J, Jordan B, Aptsiauri N (1999) An association of antiretinal antibodies and cystoid macular edema in retinitis pigmentosa patients. Am J Ophthalmol 127:565–578PubMedCrossRef
17.
go back to reference Ohguro H, Ogawa KI, Maeda T, Maeda A, Maruyama I (1999) Cancer-associated retinopathy induced by both anti-recoverin and Anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40:3160–3167PubMed Ohguro H, Ogawa KI, Maeda T, Maeda A, Maruyama I (1999) Cancer-associated retinopathy induced by both anti-recoverin and Anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40:3160–3167PubMed
18.
go back to reference Potter MJ, Adamus G, Szabo SM, Lee R, Moshaseb K, Behn D (2002) Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 134:128–130PubMedCrossRef Potter MJ, Adamus G, Szabo SM, Lee R, Moshaseb K, Behn D (2002) Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 134:128–130PubMedCrossRef
19.
go back to reference Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO (1992) “On” response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 33:477–483PubMed Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO (1992) “On” response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 33:477–483PubMed
20.
go back to reference Lei B, Bush RA, Milam AH, Sieving PA (2000) Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci 41:262–266PubMed Lei B, Bush RA, Milam AH, Sieving PA (2000) Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci 41:262–266PubMed
21.
go back to reference Gittinger JW Jr, Smith TW (1999) Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol 127:612–614PubMedCrossRef Gittinger JW Jr, Smith TW (1999) Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol 127:612–614PubMedCrossRef
22.
go back to reference Jacobson DM, Adamus G (2001) Retinal anti-biolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 131:806–808PubMedCrossRef Jacobson DM, Adamus G (2001) Retinal anti-biolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 131:806–808PubMedCrossRef
23.
go back to reference Pfohler C, Haus A, Palmowski A, Ugurel S, Ruprecht KW, Thirkill CE, Tilgen W, Reinhold U (2003) Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol 149:74–78PubMedCrossRef Pfohler C, Haus A, Palmowski A, Ugurel S, Ruprecht KW, Thirkill CE, Tilgen W, Reinhold U (2003) Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol 149:74–78PubMedCrossRef
24.
go back to reference Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases
25.
go back to reference Kellner U, Bornfeld N, Foerster MH (1995) Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol 79:746–752PubMedCrossRef Kellner U, Bornfeld N, Foerster MH (1995) Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol 79:746–752PubMedCrossRef
26.
go back to reference Kiratli H, Thirkill CE, Bilgic S, Eldem B, Kececi A (1997) Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site. Eye 11:889–892PubMed Kiratli H, Thirkill CE, Bilgic S, Eldem B, Kececi A (1997) Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site. Eye 11:889–892PubMed
27.
go back to reference Chan C, O’Day J (2001) Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 29(4):235–238 (Aug) Chan C, O’Day J (2001) Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 29(4):235–238 (Aug)
Metadata
Title
Autoimmune retinopathy: A review and summary
Authors
John R. Heckenlively
Henry A. Ferreyra
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2008
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-008-0114-7

Other articles of this Issue 2/2008

Seminars in Immunopathology 2/2008 Go to the issue

Publisher's Erratum

Immunopathology of the eye

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine